Pharma Journalist -

Ophthotech Corporation enrolled first patient in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura complement C5…
Read More...

Developer of surgical implants for treating distal extremity pathology, Centric Medical asserted that the U.S FDA has granted 510 (k) clearance to the Cannulated Screw Internal Fixation…
Read More...

Genetic screening and counseling services company, Counsyl sought approval from the New York State Department of Health to provide Prelude Prenatal Screen in New York therefore…
Read More...

Vantage Cancer Care Network into providing integrated cancer Care ventured into an agreement with Alliance Cancer Specialists, PC ensuring extensive delivery of top-notch Oncology Care…
Read More...

Sarah Cannon Research Institute and South Texas Research Accelerated Therapeutics moved to collaborate ensuring augmenting their globally acclaimed phase I drug development programs…
Read More...

Ipsen and Exelixis declared results of Phase 3 CELESTIAL trial in  patients formerly treated with advanced heptacellular carcinoma. In CELESTIAL, cabozantinib provided a statistically…
Read More...

Antibody discovery and optimization service provider, AvantGen claimed completion of its first cancer therapeutic antibody program in collaboration with Tanabe Research Laboratories USA…
Read More...

Cytovance Biologics a biopharmaceutical contract manufacturer of mammalian and microbial biologics proclaimed Edwin Miranda as Vice-President of Quality. Dr. Jesse McCool, Sr. Vice…
Read More...

Utilizing advanced analytics to offer workflow solutions and apps that advocate support solutions paving way for undisputed integration and analysis of in-vivo and in-vitro data, …
Read More...

Lustgarten Foundation alleges $22 million funding in 2017 as part of its mission to invest an unprecedented $40 million by the end of 2018. In a bid to advanced pancreatic Cancer…
Read More...